Trial Profile
A prospective observational study assessing clinical outcomes and CFTR biomarkers in patients with cystic fibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2018
Price :
$35
*
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics; Therapeutic Use
- 31 Oct 2018 New trial record
- 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society